Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

OBJECTIVE: This study was aimed at investigating the efficacy of PARP inhibitor combined with bevacizumab in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma. METHODS: A total of 84 patients with platinum-resistant recurrent ovarian epithelial carcinoma treated in our hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Li, Liu, Caixia, Li, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205723/
https://www.ncbi.nlm.nih.gov/pubmed/35720032
http://dx.doi.org/10.1155/2022/4600145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205723/
https://www.ncbi.nlm.nih.gov/pubmed/35720032
http://dx.doi.org/10.1155/2022/4600145

Ejemplares similares